T
SRPT icon

TOBAM’s Sarepta Therapeutics SRPT Stock Holding History

TOBAM’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,861
Closed -$767K – 274
2025
Q2 		$767K Buy
44,861
+7,053
+19% +$301K 0.3% 71
2025
Q1 		$2.41M Buy
37,808
+8,886
+31% +$935K 1.03% 35
2024
Q4 		$3.52M Sell
28,922
-19,968
-41% -$2.45M 1.07% 35
2024
Q3 		$6.11M Sell
48,890
-293
-0.6% -$40.5K 1.11% 35
2024
Q2 		$7.77M Sell
49,183
-70,725
-59% -$9.09M 1.22% 29
2024
Q1 		$15.5M Sell
119,908
-36,138
-23% -$4.43M 1.39% 26
2023
Q4 		$15M Buy
156,046
+7,105
+5% +$682K 1.32% 31
2023
Q3 		$18.1M Buy
148,941
+42,181
+40% +$4.77M 1.45% 29
2023
Q2 		$12.2M Buy
106,760
+94,060
+741% +$12.1M 0.92% 39
2023
Q1 		$1.75M Buy
12,700
+4,681
+58% +$607K 0.12% 96
2022
Q4 		$1.04M Buy
8,019
+4,214
+111% +$488K 0.07% 107
2022
Q3 		$421K Buy
+3,805
New +$384K 0.03% 158
2021
Q2 		– Sell
-371,107
Closed -$27.7M – 442
2021
Q1 		$27.7M Buy
371,107
+294,304
+383% +$27.2M 1.18% 34
2020
Q4 		$13.1M Sell
76,803
-29,083
-27% -$4.31M 0.58% 58
2020
Q3 		$14.9M Sell
105,886
-31,130
-23% -$4.73M 0.74% 46
2020
Q2 		$22M Buy
137,016
+59,315
+76% +$8.07M 1.41% 30
2020
Q1 		$7.6M Buy
77,701
+56,012
+258% +$6.4M 0.6% 52
2019
Q4 		$2.8M Buy
21,689
+21,193
+4,273% +$2.14M 0.17% 77
2019
Q3 		$37K Buy
+496
New +$58.6K ﹤0.01% 118
2019
Q2 		– Sell
-246
Closed -$29K – 140
2019
Q1 		$29K Sell
246
-95
-28% -$12.2K ﹤0.01% 137
2018
Q4 		$37K Buy
+341
New +$42.6K ﹤0.01% 150

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TOBAM's SRPT Position: Q3 2025 in Review

TOBAM sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 44,861 shares — an estimated $767K sold.

TOBAM first reported a position in SRPT in Q4 2018 and held it in 21 quarters. The position peaked at $27.7M in Q1 2021. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • TOBAM reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TOBAM sold 44,861 Sarepta Therapeutics shares in Q3 2025, an estimated $767K.
  • TOBAM first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 21 quarters.
  • TOBAM's Sarepta Therapeutics position peaked at $27.7M in Q1 2021.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on TOBAM's 13F filing for Q3 2025, filed 7 Nov 2025.